2018 American Transplant Congress

June 2-6, 2018 in Seattle, WA

View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Balloon-Occluded Retrograde Transvenous Obliteration (BRTO) for the Treatment of Medically Refractory Hepatic Encephalopathy (HE) in Patients with ESLD and Significant Portal-Venous Shunting

N. Presser, J. DiNorcia, V. Agopian, H. Yersiz, D. Farmer, R. Busuttil, F. Kaldas.
Bariatric Surgery before and after Kidney Transplantation: Long-Term Weight-Loss and Allograft Outcomes

J. Cohen, M. Lim, C. Tewksbury, S. Torres Landa, J. Trofe-Clark, P. Abt, N. Williams, K. Dumon, S. Goral.
Barriers and Disparities in Listing for Pediatric Solid Organ Transplant

E. A. Steinberg,¹ C. Buchanan,¹ M. Wachs,¹ S. Schmiege.²
Basiliximab Induction in HIV-Positive Renal Transplant Recipients Compared to an HIV-Negative Cohort

J. Schulte,¹ C. Richardson,¹ V. Stosor,² K. Cunningham,¹ C. D'Agostino,¹ C. Kane.¹
Basiliximab Induction in Simultaneous Liver-Kidney Transplant

C. Song, X. Luo, L. Pote, S. Strout, D. Segev, N. Desai, A. Gurakar, F. Navqi, J. Garonzik Wang.
Belatacept and Tacrolimus Corticosteroid-Free Regimens Lead to Elevated Mycophenolic Acid Exposure at 1 and 3 Months after Kidney Transplantation

A. Dao, S. Tremblay, A. Shields, A. Loethen, B. Abu Jawdeh, T. Diwan, A. Govil, E. Woodle, R. Alloway.
Belatacept in Kidney Transplant Recipients with Preformed Donor Specific Anti-HLA Antibodies: Results of the BELACOR Trial

C. Leibler,¹ F. Canoui,² M. Matignon,¹ E. Rondeau,³ A. Zarour,² A. Durrbach,⁴ S. Malard,⁵ P. Grimbert.¹
Belatacept Maintenance Immunosuppression Use and Outcomes in the Real-World Clinical Setting Using OPTN/UNOS Kidney Transplant Registry

S. Sanoff,¹ K. Ravindra,¹ W. Irish.^1,2
Belatacept-Refractory CD8⁺CD28^–CD38^hi Effector/Memory T Cells Are Targeted by mTOR Inhibition Leading to a Preferential Loss of CD40L

C. Castro Rojas,¹ A. Godarova,¹ A. Rike Shields,² R. Alloway,² M. Jordan,³ E. Woodle,² D. Hildeman.¹
Benefit of Anti-Hepatitis B Immunoglobulin(HBIG) Monotherapy Compared to HBIG Combined with Entecavir in Long Term Renal Function

J. Lee,¹ D. Kim,¹ J. Lee,² S. Kim,³ H. Lee,⁴ S. Song,⁵ J. Lee,¹ M. Ju,¹ G. Choi,¹ D. Joo,¹ J. Choi,¹ S. Kim,¹ Y. Jung.¹

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z